Medicago and Cellectis Enter into Research Agreement to Improve Therapeutic Proteins Using Nuclease Technology

PR Source Quebec City (Quebec, Canada) and Saint Paul (Minnesota, USA), January 16, 2012 – Medicago Inc. (MDG: TSX), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus Like Particles, and…